Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-Tositumomab: Long-Term follow-up of phase III randomized study SWOG-S0016

Mazyar Shadman, Hongli Li, Lisa M Rimsza, John P. Leonard, Mark S. Kaminski, Rita M. Braziel, Catherine S Perry, Ajay K. Gopal, David G. Maloney, Bruce D. Cheson, Shaker Dakhil, Michael LeBlanc, Sonali M. Smith, Richard I. Fisher, Jonathan W. Friedberg, Oliver W. Press

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133-Tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma. Understanding the long-Term outcome of patients provides a benchmark for novel treatment regimens for FL. Patients and Methods Between 2001 and 2008, 531 previously untreated patients with FL were randomly assigned to receive either six cycles of R-CHOP or six cycles of CHOP-RIT. Patients with advanced-stage disease (bulky stage II, III, or IV) of any pathologic grade (1, 2, or 3) were eligible. Results After a median follow-up of 10.3 years, 10-year estimates of progression-free and overall survival were 49% and 78% among all patients, respectively. Patients in the CHOP-RIT arm had significantly better 10-year progression-free survival compared with patients in the R-CHOP arm (56% v 42%; P = .01), but 10-year overall survival was not different between the two arms (75% v 81%; P = .13). There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% v 16.1%; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% v 1.8%; P = .058). The estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1% v 3.2%; P = .16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm compared with the R-CHOP arm (4% v 0.9%; P = .02). Conclusion Given these outstanding outcomes, immunochemotherapy should remain the standard induction approach for patients with high-risk FL until long-Term follow-up of alternative approaches demonstrates superiority.

Original languageEnglish (US)
Pages (from-to)697-703
Number of pages7
JournalJournal of Clinical Oncology
Volume36
Issue number7
DOIs
StatePublished - Mar 1 2018

Fingerprint

Follicular Lymphoma
Therapeutics
Second Primary Neoplasms
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Disease-Free Survival
Incidence
Radioimmunotherapy
Rituximab
Benchmarking
Vincristine
Prednisone
Iodine
Doxorubicin
Cyclophosphamide
Safety
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-Tositumomab : Long-Term follow-up of phase III randomized study SWOG-S0016. / Shadman, Mazyar; Li, Hongli; Rimsza, Lisa M; Leonard, John P.; Kaminski, Mark S.; Braziel, Rita M.; Perry, Catherine S; Gopal, Ajay K.; Maloney, David G.; Cheson, Bruce D.; Dakhil, Shaker; LeBlanc, Michael; Smith, Sonali M.; Fisher, Richard I.; Friedberg, Jonathan W.; Press, Oliver W.

In: Journal of Clinical Oncology, Vol. 36, No. 7, 01.03.2018, p. 697-703.

Research output: Contribution to journalArticle

Shadman, M, Li, H, Rimsza, LM, Leonard, JP, Kaminski, MS, Braziel, RM, Perry, CS, Gopal, AK, Maloney, DG, Cheson, BD, Dakhil, S, LeBlanc, M, Smith, SM, Fisher, RI, Friedberg, JW & Press, OW 2018, 'Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-Tositumomab: Long-Term follow-up of phase III randomized study SWOG-S0016', Journal of Clinical Oncology, vol. 36, no. 7, pp. 697-703. https://doi.org/10.1200/JCO.2017.74.5083
Shadman, Mazyar ; Li, Hongli ; Rimsza, Lisa M ; Leonard, John P. ; Kaminski, Mark S. ; Braziel, Rita M. ; Perry, Catherine S ; Gopal, Ajay K. ; Maloney, David G. ; Cheson, Bruce D. ; Dakhil, Shaker ; LeBlanc, Michael ; Smith, Sonali M. ; Fisher, Richard I. ; Friedberg, Jonathan W. ; Press, Oliver W. / Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-Tositumomab : Long-Term follow-up of phase III randomized study SWOG-S0016. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 7. pp. 697-703.
@article{2d31db2fb3bd4afa9efe2fa6c3300891,
title = "Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-Tositumomab: Long-Term follow-up of phase III randomized study SWOG-S0016",
abstract = "Purpose SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133-Tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma. Understanding the long-Term outcome of patients provides a benchmark for novel treatment regimens for FL. Patients and Methods Between 2001 and 2008, 531 previously untreated patients with FL were randomly assigned to receive either six cycles of R-CHOP or six cycles of CHOP-RIT. Patients with advanced-stage disease (bulky stage II, III, or IV) of any pathologic grade (1, 2, or 3) were eligible. Results After a median follow-up of 10.3 years, 10-year estimates of progression-free and overall survival were 49{\%} and 78{\%} among all patients, respectively. Patients in the CHOP-RIT arm had significantly better 10-year progression-free survival compared with patients in the R-CHOP arm (56{\%} v 42{\%}; P = .01), but 10-year overall survival was not different between the two arms (75{\%} v 81{\%}; P = .13). There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1{\%} v 16.1{\%}; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9{\%} v 1.8{\%}; P = .058). The estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1{\%} v 3.2{\%}; P = .16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm compared with the R-CHOP arm (4{\%} v 0.9{\%}; P = .02). Conclusion Given these outstanding outcomes, immunochemotherapy should remain the standard induction approach for patients with high-risk FL until long-Term follow-up of alternative approaches demonstrates superiority.",
author = "Mazyar Shadman and Hongli Li and Rimsza, {Lisa M} and Leonard, {John P.} and Kaminski, {Mark S.} and Braziel, {Rita M.} and Perry, {Catherine S} and Gopal, {Ajay K.} and Maloney, {David G.} and Cheson, {Bruce D.} and Shaker Dakhil and Michael LeBlanc and Smith, {Sonali M.} and Fisher, {Richard I.} and Friedberg, {Jonathan W.} and Press, {Oliver W.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1200/JCO.2017.74.5083",
language = "English (US)",
volume = "36",
pages = "697--703",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-Tositumomab

T2 - Long-Term follow-up of phase III randomized study SWOG-S0016

AU - Shadman, Mazyar

AU - Li, Hongli

AU - Rimsza, Lisa M

AU - Leonard, John P.

AU - Kaminski, Mark S.

AU - Braziel, Rita M.

AU - Perry, Catherine S

AU - Gopal, Ajay K.

AU - Maloney, David G.

AU - Cheson, Bruce D.

AU - Dakhil, Shaker

AU - LeBlanc, Michael

AU - Smith, Sonali M.

AU - Fisher, Richard I.

AU - Friedberg, Jonathan W.

AU - Press, Oliver W.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133-Tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma. Understanding the long-Term outcome of patients provides a benchmark for novel treatment regimens for FL. Patients and Methods Between 2001 and 2008, 531 previously untreated patients with FL were randomly assigned to receive either six cycles of R-CHOP or six cycles of CHOP-RIT. Patients with advanced-stage disease (bulky stage II, III, or IV) of any pathologic grade (1, 2, or 3) were eligible. Results After a median follow-up of 10.3 years, 10-year estimates of progression-free and overall survival were 49% and 78% among all patients, respectively. Patients in the CHOP-RIT arm had significantly better 10-year progression-free survival compared with patients in the R-CHOP arm (56% v 42%; P = .01), but 10-year overall survival was not different between the two arms (75% v 81%; P = .13). There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% v 16.1%; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% v 1.8%; P = .058). The estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1% v 3.2%; P = .16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm compared with the R-CHOP arm (4% v 0.9%; P = .02). Conclusion Given these outstanding outcomes, immunochemotherapy should remain the standard induction approach for patients with high-risk FL until long-Term follow-up of alternative approaches demonstrates superiority.

AB - Purpose SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133-Tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma. Understanding the long-Term outcome of patients provides a benchmark for novel treatment regimens for FL. Patients and Methods Between 2001 and 2008, 531 previously untreated patients with FL were randomly assigned to receive either six cycles of R-CHOP or six cycles of CHOP-RIT. Patients with advanced-stage disease (bulky stage II, III, or IV) of any pathologic grade (1, 2, or 3) were eligible. Results After a median follow-up of 10.3 years, 10-year estimates of progression-free and overall survival were 49% and 78% among all patients, respectively. Patients in the CHOP-RIT arm had significantly better 10-year progression-free survival compared with patients in the R-CHOP arm (56% v 42%; P = .01), but 10-year overall survival was not different between the two arms (75% v 81%; P = .13). There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% v 16.1%; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% v 1.8%; P = .058). The estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1% v 3.2%; P = .16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm compared with the R-CHOP arm (4% v 0.9%; P = .02). Conclusion Given these outstanding outcomes, immunochemotherapy should remain the standard induction approach for patients with high-risk FL until long-Term follow-up of alternative approaches demonstrates superiority.

UR - http://www.scopus.com/inward/record.url?scp=85042628842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042628842&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.74.5083

DO - 10.1200/JCO.2017.74.5083

M3 - Article

C2 - 29356608

AN - SCOPUS:85042628842

VL - 36

SP - 697

EP - 703

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -